Would New SARS-CoV-2 Variants Change the War against COVID-19?

Elrashdy M. Redwan, Fatma Elrashdy, Alaa A. A. Aljabali, Wagner Baetas-da-Cruz, Debmalya Barh, Adam M. Brufsky, Sk. Sarif Hassan, Kenneth Lundstrom, Ángel Serrano-Aroca, Kazuo Takayama, Murtaza M. Tambuwala, Bruce D. Uhal, Vladimir N. Uversky

Research output: Contribution to journalArticlepeer-review

4 Citations (Scopus)
35 Downloads (Pure)


The scientific, private, and industrial sectors use a wide variety of technological platforms available to achieve protection against SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), including vaccines. However, the virus evolves continually into new highly virulent variants, which might overcome the protection provided by vaccines and may re-expose the population to infections. Mass vaccinations should be continued in combination with more or less mandatory non-pharmaceutical interventions. Therefore, the key questions to be answered are: (i) How to identify the primary and secondary infections of SARS-CoV-2? (ii) Why are neutralizing antibodies not long-lasting in both cases of natural infections and post-vaccinations? (iii) Which are the factors responsible for this decay in neutralizing antibodies? (iv) What strategy could be adapted to develop long-term herd immunity? (v) Is the Spike protein the only vaccine target or is a vaccine cocktail better?
Original languageEnglish
Pages (from-to)229-237
Number of pages9
Issue number2
Publication statusPublished (in print/issue) - 29 Apr 2022


  • SARS-CoV-2
  • COVID-19
  • variant
  • sublineage
  • transmission
  • immunity
  • infection
  • vaccination
  • non-pharmaceutical interventions


Dive into the research topics of 'Would New SARS-CoV-2 Variants Change the War against COVID-19?'. Together they form a unique fingerprint.

Cite this